Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Merck Climbs on the Emerging Markets Bandwagon

publication date: Nov 11, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Merck wants to be either number one or two in China’s healthcare market within the next five to seven years. Much like all the major multinational pharmas, Merck is de-emphasizing its old business model, based on patented blockbuster drugs for Western markets, and turning to emerging markets for its future growth. The company wants emerging markets to generate one-fourth of all revenue by 2013, up from 18% currently. More details....

Stock Symbol: (NYSE: MRK)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...